Asset Details
Do you wish to reserve the book?
Effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps
Do you wish to request the book?
Effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effectiveness of dupilumab in chronic rhinosinusitis with nasal polyps
2025
Overview
[Please see PDF for full article text] [Please see PDF for full article text] Objectives: To evaluate dupilumab's outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP) cases. Methods: A retrospective analysis was carried out at Dr. Sulaiman Al Habib Hospitals, Riyadh, Saudi Arabia on 145 adult CRSwNP patients treated with dupilumab between January 2020 and December 2023 following the European position paper on rhinosinusitis and nasal polyps 2020 guidelines. Primary outcomes included changes in Lund-Mackay computed tomography (CT) scores, immunoglobulin E levels, and visual analog scale (VAS) smell score over +12 months. Results: Significant improvements were noted post-treatment. Lund-Mackay CT scores decreased from 12.5 to 5.5 (p<0.001), and VAS smell scores dropped from 10.0 to 0.0 (p <0.001). Immunoglobulin E levels reduced from 250.5 to 63.5 (p<0.001). After treatment, 93.3% of patients avoided sinus surgery, 78.6% reported improved asthma status, and 60% used dupilumab as monotherapy. Conclusion: This study supports dupilumab's effectiveness in treating severe CRSwNP, showing significant improvements in CT imaging and overall medical condition over 12 months. Dupilumab reduced systemic corticosteroid use and rescue surgeries. While promising, further trials are needed to validate its use as monotherapy. Identifying those who gain most from biologic therapy is crucial. Keywords: dupilumab, biological therapy, rhinosinusitis, type 2 inflammation, asthma, nasal polyposis
Publisher
Saudi Medical Journal
Subject
